Company Quick10K Filing
Remsleep Holdings
Price0.03 EPS-0
Shares73 P/E-1
MCap2 P/FCF-15
Net Debt0 EBIT-3
TEV2 TEV/EBIT-1
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-03-31 Filed 2020-05-18
10-K 2019-12-31 Filed 2020-04-10
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-15
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-03-29
10-Q 2018-09-30 Filed 2018-11-13
10-Q 2018-06-30 Filed 2018-08-17
10-Q 2018-03-31 Filed 2018-06-28
10-K 2017-12-31 Filed 2018-06-28
10-Q 2017-09-30 Filed 2018-02-06
10-Q 2017-06-30 Filed 2017-08-21
10-Q 2017-03-31 Filed 2017-05-18
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2017-02-23
10-Q 2016-06-30 Filed 2017-02-22
10-Q 2016-03-31 Filed 2017-02-22
10-K 2015-12-31 Filed 2017-02-15
10-Q 2015-09-30 Filed 2017-01-04
10-Q 2015-06-30 Filed 2016-12-30
10-Q 2015-03-31 Filed 2016-12-30
10-K 2014-12-31 Filed 2016-04-14
10-Q 2014-06-30 Filed 2015-03-02
10-Q 2014-06-30 Filed 2015-03-02
10-Q 2014-03-31 Filed 2015-02-25
10-K 2013-12-31 Filed 2015-02-04
10-Q 2013-09-30 Filed 2013-12-03
10-Q 2013-06-30 Filed 2013-08-26
10-Q 2013-03-31 Filed 2013-06-27
10-Q 2012-09-30 Filed 2012-11-19
10-Q 2012-06-30 Filed 2012-08-08
10-Q 2012-03-31 Filed 2012-05-15
10-Q 2011-09-30 Filed 2011-11-21
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-04-15
10-Q 2010-09-30 Filed 2010-11-22
10-Q 2010-06-30 Filed 2010-08-12
10-Q 2010-03-31 Filed 2010-05-18
10-K 2009-12-31 Filed 2010-04-07
8-K 2020-01-30
8-K 2020-01-27
8-K 2018-07-26
8-K 2018-01-29

RMSL 10Q Quarterly Report

Part I - Financial Information
Item 1. Financial Statements
Note 1 - Background
Note 2 - Summary of Significant Accounting Policies
Note 3 - Going Concern
Note 4 - Property & Equipment
Note 5 - Loans Payable
Note 6 - Convertible Notes
Note 7 - Related Party Transactions
Note 8 - Common Stock
Note 9 - Preferred Stock
Note 10 - Warrants
Note 11 - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Plan of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-31.1 f10q0320ex31-1_remsleep.htm
EX-32.1 f10q0320ex32-1_remsleep.htm

Remsleep Holdings Earnings 2020-03-31

Balance SheetIncome StatementCash Flow
0.3-0.5-1.4-2.2-3.1-3.92012201420172020
Assets, Equity
0.5-0.0-0.6-1.1-1.7-2.22011201220132015
Rev, G Profit, Net Income
0.80.50.2-0.2-0.5-0.82012201420172020
Ops, Inv, Fin

10-Q 1 f10q0320_remsleepholdings.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to __________

 

Commission File Number: 000-53450

 

REMSLEEP HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada   47-5386867
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

2202 N. West Shore Blvd, Suite 200, Tampa. FL 33607

(Address of principal executive offices) (Zip Code)

 

813-367-3855

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of as of May 11, 2020, there were 190,882,266 shares of common stock outstanding.

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

i

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

REMSLEEP HOLDINGS, INC.

 

 

1

 

 

REMSLEEP HOLDINGS, INC.

CONDENSED BALANCE SHEETS

 

 

  

March 31,

2020

  

December 31,

2019

 
   (Unaudited)   (Audited) 
ASSETS        
Current assets:        
Cash  $253,667   $119,574 
Inventory deposit   8,000    8,000 
Inventory   1,039    - 
Prepaid expenses   -    7,909 
Total current assets   262,706    135,483 
           
Other asset   10,000    10,000 
Property and equipment, net   104,197    107,814 
           
Total Assets  $376,903   $253,297 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current Liabilities:          
Accounts payable  $241,677   $258,198 
Accrued compensation   14,000    15,000 
Accrued interest   31,806    27,953 
Accrued interest – related party   28,045    22,399 
Convertible Notes, net of discount of $267,858 and $164,998, respectively   145,742    76,996 
Derivative Liability   665,321    626,831 
Loan payable – related party   179,191    179,191 
Loans payable   55,738    56,556 
           
Total Liabilities   1,361,520    1,263,124 
           
Commitments and Contingencies   -    - 
           
STOCKHOLDERS’ DEFICIT:          
           
Series A preferred stock, $0.001 par value, 5,000,000 shares authorized, 4,000,000 and issued and outstanding   125,000    125,000 
Series B preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued   -    - 
Series C preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued   -    - 
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 172,780,003 and 116,269,466 shares issued and outstanding, respectively   172,778    116,268 
Common stock to be issued   -    - 
Additional paid in capital   4,384,966    4,139,395 
Accumulated Deficit   (5,667,361)   (5,390,490)
TOTAL STOCKHOLDERS’ DEFICIT   (984,617)   (1,009,827)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $376,903   $253,297 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

2

 

 

REMSLEEP HOLDINGS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

  

For the
Three Months Ended

March 31,

 
   2020   2019 
         
Operating Expenses:        
Professional fees  $9,725   $15,500 
Compensation expense – related party   21,000    18,000 
General and administrative   48,667    16,369 
           
Total operating expenses   79,392    49,869 
           
Loss from operations   (79,392)   (49,869)
           
Other expenses:          
Interest expense   (14,900)   (10,487)
Discount amortization   (145,740)   (43,953)
Loss on issuance of convertible debt   (186,365)   (125,709)
Change in fair value of derivative   152,875    (361,714)
Total other expense   (194,130)   (541,863)
           
Loss before income taxes   (273,522)   (591,732)
           
Provision for income taxes   -    - 
           
Net Loss  $(273,522)  $(591,732)
           
Net loss per share, basic and diluted  $(0.00)  $(0.12)
           
Weighted average common shares outstanding, basic and diluted   149,584,188    4,736,389 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

 

REMSLEEP HOLDINGS, INC.

CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2019

(UNAUDITED)

 

 

  

Series A Preferred Shares

   Series A Preferred Stock Amount   Common Shares   Common Stock Amount   Common stock to be issued   Additional Paid-in Capital   Accumulated Deficit   Total 
Balance, December 31, 2018   3,500,000    105,000    4,315,894   $4,316   $228,604   $584,017   $(1,502,022)  $(580,085)
Common stock issued for conversion of debt   -    -    1,523,291    1,523    -    49,604    -    51,127 
Net loss for the three months ended March 31, 2019   -    -    -    -    -    -    (591,732)   (591,732)
Balance, March 31, 2019   3,500,000   $105,000    5,839,185   $5,839   $228,604   $633,621   $(2,093,754)  $(1,120,690)

 

 

REMSLEEP HOLDINGS, INC.

CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2020

(UNAUDITED)

 

 

   Series A Preferred Shares   Series A Preferred Stock Amount   Common Shares   Common Stock Amount   Additional Paid-in Capital   Accumulated Deficit   Total 
Balance, December 31, 2019   4,000,000   $125,000    116,269,466   $116,268   $4,139,395   $(5,390,490)  $(1,009,827)
Common stock issued for conversion of debt   -    -    19,741,098    19,741    278,991    -    298,732 
Warrants converted to common stock   -    -    36,769,439    36,769    (36,769)   -    - 
Warrant down round protection   -    -    -    -    3,349    (3,349)   - 
Net loss   -    -    -    -    -    (273,522)   (273,522)
Balance, March 31, 2020   4,000,000   $125,000    172,780,003   $172,778   $4,384,966   $(5,667,361)  $(984,617)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

 

REMSLEEP HOLDINGS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

  

For the Three Months Ended

March 31,

 
   2020   2019 
Cash Flows from Operating Activities:        
Net loss  $(273,522)  $(591,732)
Adjustments to reconcile net loss to net cash used in operations:          
Depreciation expense   11,117    1,402 
Change in fair value of derivative   (152,875)   361,714 
Discount amortization   145,740    43,953 
Loss on issuance of convertible debt   186,385    125,709 
Changes in Operating Assets and Liabilities          
Prepaid expenses   7,909    (5,334)
Inventory   (1,039)   - 
Accounts payable   (16,520)   8,484 
Accrued officer compensation   (1,000)   3,500 
Accrued interest   10,570    4,755 
Accrued interest – related party   5,646    5,523 
Net cash used in operating activities   (77,589)   (42,026)
           
Cash Flows from Investing Activities:          
Purchase of equipment   (7,500)   (24,490)
Net Cash used in investing activities   (7,500)   (24,490)
           
Cash Flows from Financing Activities:          
Repayment of loans   (818)   (772)
Proceeds from convertible notes payable   220,000    95,000 
Net cash provided by financing activities   219,182    94,228 
           
Net increase in cash   134,093    27,712 
Cash at beginning of the period   119,574    16,640 
Cash at end of the period  $253,667   $44,352 
           
Supplemental cash flow information:          
Interest paid in cash  $161   $- 
Taxes paid  $-   $- 
Supplemental non-cash disclosure:          
Common stock issued for conversion of debt  $82,233   $16,026 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

5

 

 

REMSLEEP HOLDINGS, INC.

 

NOTES TO CONDENSED FINANCIAL STATEMENTS

March 31, 2020

(Unaudited)

 

NOTE 1 - BACKGROUND

 

Business Activity

REMSleep Holdings, Inc. (the “Company”) was incorporated in the State of Nevada on June 6, 2007. On January 5, 2015 the name of the Company was changed to REMSleep Holdings, Inc. and the business model was changed to reflect the new direction of the Company – to develop and distribute products to help people affected by sleep apnea. Effective January 1, 2015, we completed an exchange agreement to purchase 100% of the outstanding interests of REMSleep LLC in exchange for 50,000,000 common shares of REMSleep Holdings, Inc.’s stock, at which time REMSleep LLC became our wholly-owned subsidiary and adopted their business of developing and distributing our sleep apnea products. On January 5, 2015, we changed our name to REMSleep Holdings, Inc. to reflect our new business model.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

These unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). These financial statements and the notes attached hereto should be read in conjunction with the financial statements and notes included in the Company’s 10-K for its fiscal year ended December 31, 2019. In the opinion of the Company, all adjustments, including normal recurring adjustments necessary to present fairly the financial position of the Company, as of March 31, 2020 and the results of its operations and cash flows for the three months then ended have been included. The results of operations for the interim period are not necessarily indicative of the results for the full year ending December 31, 2020.

 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.  The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

 

Level 1: Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2: Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3: Pricing inputs that are generally unobservable inputs and not corroborated by market data.

 

The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the short maturity of those instruments. The Company’s notes payable approximates the fair value of such instruments as the notes bear interest rates that are consistent with current market rates.

 

6

 

 

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of March 31, 2020:

 

Description  Level 1   Level 2   Level 3   Total Gains and (Losses) 
Derivative      -       -    665,321    152,875 
Total  $-   $-   $665,321   $152,875 

 

December 31, 2019:

 

Description  Level 1   Level 2   Level 3   Total Gains and (Losses) 
Derivative      -       -    626,831    445,318 
Total  $-   $-   $626,831   $445,318 

 

Recently Adopted Accounting Pronouncements

 

The Company has implemented all new accounting pronouncements that are in effect.  These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

NOTE 3 - GOING CONCERN

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $5,667,361 at March 31, 2020, had a net loss of $273,522 (including approximately $272,000 on non-cash expense and losses related to convertible debt) and net cash used in operating activities of $77,589 for the three months ended March 31, 2020. The Company’s ability to raise additional capital through the future issuances of common stock and/or debt financing is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors over the next twelve months raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

The Company is in the final stages of product development and plans to begin selling its product in 2020. The Company will continue to finance its operations through debt and/or equity financing as needed.

 

NOTE 4 - PROPERTY & EQUIPMENT

 

Long lived assets, including property and equipment and certain intangible assets to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Impairment losses are recognized if expected future cash flows of the related assets are less than their carrying values. Measurement of an impairment loss is based on the fair value of the asset. Long-lived assets and certain identifiable intangibles to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

 

Property and Equipment and intangible assets are first recorded at cost. Depreciation and/or amortization is computed using the straight-line method over the estimated useful lives of the various classes of assets as follows between three and five years.

 

Maintenance and repair expenses, as incurred, are charged to expense. Betterments and renewals are capitalized in plant and equipment accounts. Cost and accumulated depreciation applicable to items replaced or retired are eliminated from the related accounts with any gain or loss on the disposition included as income.

 

7

 

  

Assets stated at cost, less accumulated depreciation consisted of the following:

 

   March 31, 2020   December 31,
2019
 
Furniture/fixtures  $14,904   $14,904 
Office equipment   7,136    7,136 
Automobile   16,979    16,963 
Tooling/Molds   112,785    105,301 
Less: accumulated depreciation   (47,607)   (36,490)
Fixed assets, net  $104,197   $107,814 

 

Depreciation expense

Depreciation expense for the three months ended March 31, 2020 and 2019 was $11,117 and $1,402, respectively.

 

NOTE 5 - LOANS PAYABLE

 

On October 24, 2017, the Company was notified that a petition had been filed in the Iowa District Court for Polk County by a Mr. John M. Wesson for failure to repay a loan. Mr. Wesson had loaned the Company $30,000 and $20,000 on October 24, 2012 and June 12, 2013, respectively. The loans were to accrue interest at 5%. On April 26, 2018, the Company agreed to repay the loan in full including accrued interest and $5,000 for legal fees. As of March 31, 2020, there is $45,000 and $17,652 of principal and interest due on this loan. As of December 31, 2019, there was $45,000 and $17,901 of principal and interest due on this loan.

 

On March 23, 2018, the Company purchased an automobile. The purchase price was $16,963 The interest rate on the loan is 5.8% and matures on April 7, 2023. Payments on the loan, consisting of principal and interest, are $327 per month. As of March 31, 2020, the balance on this loan is $10,738.

 

NOTE 6 - CONVERTIBLE NOTES

 

The following table summarizes the convertible notes and related activity as of March 31, 2020:

 

Note Holder  Date  Maturity Date  Interest   Balance
December 31,
2019
   Additions   Conversions   Balance
March 31, 2020
 
Odyssey Capital Funding, LLC  5/3/2019  5/3/2020   12%   35,000    -    (35,000)   - 
Armada Investment Fund LLC  5/30/2019  2/29/2020   12%   20,850    -    (20,850)   - 
BHP Capital NY Inc.  5/30/2019  2/29/2020   12%   7,394    -    (7,394)   - 
Jefferson Street Capital LLC  5/30/2019  2/29/2020   12%   13,750    -    (13,750)   - 
Armada Investment Fund LLC  10/4/2019  7/4/2020   12%   55,000    -    -    55,000 
BHP Capital NY Inc.  10/4/2019  7/4/2020   12%   55,000    -    -    55,000 
Jefferson Street Capital LLC  10/4/2019  7/4/2020   12%   55,000    -    -    55,000 
Power Up Lending Group LTD  1/27/2020  1/27/2021   12%   -    168,300    -    168,300 
Power Up Lending Group LTD  3/2/2020  3/2/3021   12%   -    80,300    -    80,300 
      Total   $241,994   $248,600   $(76,994)  $413,600 
   Less debt discount    (164,998)             (267,858)
              $76,996             $145,742 

 

A summary of the activity of the derivative liability for the notes above is as follows:

 

Balance at December 31, 2018   96,110 
Increase to derivative due to new issuances   1,955,295 
Decrease to derivative due to conversion   (979,290)
Derivative loss due to mark to market adjustment   (445,284)
Balance at December 31, 2019  $626,831 
Increase to derivative due to new issuances   406,365 
Decrease to derivative due to conversion   (215,000)
Derivative loss due to mark to market adjustment   (152,875)
Balance at March 31, 2020  $665,321 

 

8

 

 

A summary of quantitative information about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s derivative liability that are categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2020 is as follows:

 

Inputs   March 31,
2020
    Initial
Valuation
 
Stock price   $ .0069     $ .0094 - .55  
Conversion price   $ .003 - .007     $ 003 - .244  
Volatility (annual)     330.6 – 374 %     261.04% - 410.61 %
Risk-free rate     .11% - .17 %     .89% - 2.58 %
Dividend rate     -       -  
Years to maturity     .26 - .92       .75 - 1  

 

A summary of quantitative information about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s derivative liability that are categorized within Level 3 of the fair value hierarchy at the time of conversion is as follows:

 

Inputs      
Stock price   $ .0106 - .0296  
Conversion price   $ .0034 - .0046  
Volatility (annual)     312.5 – 363.9  
Risk-free rate     1.54% - 1.56 %
Dividend rate     -  
Years to maturity     .13 - .35  

 

The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management

 

NOTE 7 - RELATED PARTY TRANSACTIONS

 

The Company has received support from parties related through common ownership and directorship. These loans are unsecured, and due on demand. As of March 31, 2020 and December 31, 2019, the balance due on these loans is $179,191 and $179,191, respectively. Beginning on January 1, 2019, the balance due accrues interest at 12.5%. As of March 31, 2020, total accrued interest is $28,045.

 

The Company executed a new employment agreement with Mr. Wood on April 1, 2019. Per the terms of the agreement Mr. Wood is to be compensated $4,000 per month. The agreement expired on April 1, 2020 and has been renewed for another year.

 

The Company executed an employment agreement with its Chairman, Russell Bird, on January 1, 2019. Per the terms of the agreement, which is effective for one year, Mr. Bird is to be compensated $3,000 per month. As of March 31, 2020, there is $14,000 of accrued compensation due to Mr. Bird. Mr. Bird’s employment agreement has been renewed in 2020.

 

NOTE 8 - COMMON STOCK

 

During the three months ended March 31, 2020, Armada Capital Partners LLC converted $20,850 and $110 of principal and interest, respectively, into 5,202,346 shares of common stock.

 

During the three months ended March 31, 2020, BHP Capital NY Inc converted $7,394 and $35 of principal and interest, respectively, into 1,919,620 shares of common stock.

 

9

 

 

During the three months ended March 31, 2020, Jefferson Street Capital LLC converted $13,750 of principal and $2,205 of interest, respectively, into 3,989,090 shares of common stock.

 

During the three months ended March 31, 2020, Odyssey Capital Funding LLC converted $35,000 of principal and $2,890 of interest, respectively, into 8,630,042 shares of common stock.

 

During the three months ended March 31, 2020, 36,769,439 shares of common stock were issued in conversion of 46,675,330 warrants.

 

NOTE 9 - PREFERRED STOCK

 

The Company is currently authorized to issue 5,000,000 shares of Series A Preferred Stock, par value $0.001 per share value with 1:25 voting rights. The Series A Preferred Stock ranks equal to the common stock on liquidation, pays no dividend and is convertible to common stock for one share of common for one share of Series A Preferred Stock.

 

The Company is currently authorized to issue 5,000,000 shares of Series B Preferred Stock, par value $0.001 per share. Each share of Series B Preferred Stock has a 1:100 voting right and is convertible into 100 shares of common stock. No dividends will be paid and in the event of liquidation all shares of Series B will automatically convert into common stock. There are no shares of Series B Preferred Stock issued and outstanding.

 

The Company is currently authorized to issue 5,000,000 shares of Series C Preferred Stock, par value $0.001 per share value. Each share of Series C Preferred Stock has a 1:50 voting right and is convertible into 50 shares of common stock. No dividends will be paid and in the event of liquidation all shares of Series C will automatically convert into common stock. There are no shares of Series C Preferred Stock issued and outstanding.

 

NOTE 10 - WARRANTS

 

On May 30, 2019, the Company issued 1,500,000 warrants in conjunction with convertible debt. The warrants are exercisable for 3 years at $.10 per share. The warrants were evaluated for purposes of classification between liability and equity. The warrants do not contain features that would require a liability classification and are therefore considered equity. The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

 

Using the fair value calculation, the relative fair value between the debt issued and the warrants was calculated to determine the warrants recorded equity amount of $41,853, accounted for in additional paid in capital.

 

Warrants   1,500,000 
Share price  $0.045 
Exercise Price  $0.07 
Term   3 years 
Volatility   406%
Risk Free Interest Rate   2.0%
Dividend rate   - 

  

On October 4, 2019, the Company issued 1,500,000 warrants in conjunction with convertible debt. The warrants are exercisable for 3 years at $0.10 per share. The warrants were evaluated for purposes of classification between liability and equity. The warrants do not contain features that would require a liability classification and are therefore considered equity. The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

 

Using the fair value calculation, the relative fair value between the debt issued and the warrants was calculated to determine the warrants recorded equity amount of $36,606, accounted for in additional paid in capital.

 

The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

 

Warrants   1,500,000 
Share price  $0.0245 
Exercise Price  $0.10 
Term   3 years 
Volatility   356.53%
Risk Free Interest Rate   1.35%
Dividend rate   - 

 

10

 

 

On January 22, 2020, the Company issued 63,236,369 additional warrants as part of the down round protection provisions. The adjusted exercise price was $0.00385. The warrants were evaluated for purposes of classification between liability and equity. The warrants do not contain features that would require a liability classification and are therefore considered equity.

 

The Black Scholes pricing model was used to estimate the fair value of the Warrants issued with the following inputs:

 

Warrants     63,236,369  
Share price   $ 0.0249  
Exercise Price   $ 0.00385  
Term     2.35 – 2.70 years  
Volatility     392.73 – 410.10%  
Risk Free Interest Rate     1.52 – 1.53 %
Dividend rate     -  

 

A summary of the status of the Company’s outstanding stock warrants and changes during the year is presented below:

 

Activity for the three months ended March 31, 2020 is as follows: 

 

   Number of
Warrants
   Weighted
Average
Exercise Price
   Weighted
Average
Remaining
Contract
Term
   Aggregate Intrinsic Value 
Outstanding at December 31, 2019   -   $-    -      
Granted   3,000,000    0.07    2.59      
Expired   -    -    -      
Exercised   -    -    -      
Outstanding at December 31, 2019   3,000,000    0.07    2.59      
Granted   63,236,369    0.00385    2.56      
Expired   -    -    -      
Exercised   (46,675,330)   -    -      
Exercisable at March 31, 2020   19,561,039   $0.00385    2.51   $       - 

 

Range of Exercise
Prices
   Number Outstanding
3/31/2020
   Weighted Average Remaining
Contractual Life
  Weighted Average
Exercise Price
 
$0.00385    19,561,039   2.51 years  $0.00385 

  

The aggregate intrinsic value represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price as of March 31, 2020, which would have been received by the warrant holder had the warrant holder exercised their warrants as of that date.

 

NOTE 11 - SUBSEQUENT EVENTS

 

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements other than the following.

 

On January 30, 2020, the World Health Organization declared the COVID-19 (coronavirus) outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates. The Company continues to execute its business plan. At the present time, the Company can not predict the full impact of the COVID-19 virus on its business. Our projections on spending, product development and milestone achievements are likely to be further revised as new information is obtained.

 

During April 1, 2020, the Company sold 11,000,000 shares of common stock for total cash proceeds of $55,000. The shares were sold pursuant to the offering statement recently filed with the SEC.

 

Subsequent to March 31, 2020, the Company issued 7,105, 263 shares of common stock in conversion of warrants held BHP Capital NY Inc.

 

11

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS.

 

Forward-looking Statements

 

There are “forward-looking statements” contained in this quarterly report. All statements that express expectations, estimates, forecasts or projections are forward-looking statements. In addition, other written or oral statements which constitute forward-looking statements may be made by us or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “project,” “forecast,” “may,” “should,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in or suggested by such forward-looking statements. We undertake no obligation to update or revise any of the forward-looking statements after the date of this quarterly report to conform forward-looking statements to actual results. Important factors on which such statements are based are assumptions concerning uncertainties, including but not limited to, uncertainties associated with the following:

 

  Inadequate capital and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;
  Our failure to earn revenues or profits;
  Inadequate capital to continue business;
  Volatility or decline of our stock price;
  Potential fluctuation in quarterly results;
  Rapid and significant changes in markets;
  Litigation with or legal claims and allegations by outside parties; and
  Insufficient revenues to cover operating costs.

 

The following discussion should be read in conjunction with the financial statements and the notes thereto which are included in this quarterly report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ substantially from those anticipated in any forward-looking statements included in this discussion as a result of various factors.

 

Overview

 

We were incorporated in the State of Nevada on June 6, 2007. On August 26, 2010, we changed our name from Bella Viaggio, Inc. to Kat Gold Holdings Corp. Effective January 1, 2015, we completed an exchange agreement to purchase 100% of the outstanding interests of RemSleep LLC in exchange for 50,000,000 shares of common stock of RemSleep Holdings, Inc. at which time RemSleep LLC became our wholly-owned subsidiary and we adopted their business of developing and distributing sleep apnea products. On January 5, 2015, we changed our name to REMSleep Holdings, Inc. to reflect our new business model.

 

Our officers have 35 years of sleep-industry experience, including having been employed at sleep industry companies. Our officers invented our DeltaWave CPAP interface (the “DeltaWave”) as an innovative new device to treat patients with sleep apnea. The patent-pending DeltaWave product is a nasal-pillows type interface that will result in better comfort and, therefore, better compliance since it was specifically designed with unique airflow characteristics to enable patients with sleep apnea to breathe normally. A survey that appeared in DME Business found that 89% of patients stated that mask-interface comfort was their primary concern. The primary issue that we have addressed with the DeltaWave is the “work of breathing” component. We believe that our DeltaWave is designed to effectively address the stubborn issues that continue to affect a patient’s ability to comply with treatment, as follows:

 

  Does not disrupt normal breathing mechanics;
  Is not claustrophobic;
  Causes zero work of breathing (WOB);
  Minimizes or eliminates drying of the sinuses;
  Uses less driving pressure; and
  Allows users to feel safe and secure while sleeping.

 

Pending adequate financing, we plan to conduct clinical trials to test product effectiveness.

 

12

 

 

On June 28, 2016, we applied for a patent for a new, innovative sleep apnea product that serves as an interface for the delivery of CPAP therapy and other respiratory needs. Our goal is to develop sleep products that achieve optimum compliance and comfort for CPAP patients.

 

Our website is located at: http://www.remsleeptech.com. The contents of our website are not incorporated by reference into this report.

 

Results of Operations

 

The three months ended March 31, 2020 compared to the three months ended March 31, 2019

 

We have not generated revenue in the three months ended March 31, 2020 and 2019.

 

Professional fees were $9,725 compared to $15,500 for the three months ended March 31, 2020 and 2019, respectively, a decrease of $5,775, or 37.3%. Professional fees consist mostly of accounting, audit and legal fees. The decrease in the current period is due to a decrease in audit fees billed during the first quarter of 2020.

 

Compensation expense was $21,000 and $18,000 for the three months ended March 31, 2020 and 2019, respectively, an increase of $3,000. The increase is due to an increase in monthly salary to our CEO.

 

General and administrative expense was $48,667 and $16,369 for the three months ended March 31, 2020 and 2019, respectively, an increase of $32,298, or 197.3%. The increase in the current period can be largely attributed to an increase in depreciation, development and web design expense.

 

Total other expense for the three months ended March 31, 2020, was $194,130. Other expense includes $145,740 of debt discount amortization, a gain in the change of fair value of $152,875, a loss on the issuance of convertible debt of $186,365 (expenses related to our convertible debt) and interest expense of $14,900. In the prior period we had $43,953 of debt discount amortization, a loss on the issuance of convertible debt of $125,709, a loss in the change of fair value of $361,714 and $10,487 of interest expense.

 

Net Loss

For the three months ended March 31, 2020, we had a net loss of $273,522 as compared to a net loss of $591,732 for the three months ended March 31, 2019. Our net loss was lower in the current period primarily due primarily to the decrease other expenses as a result of the change in fair value of our derivatives.

 

Liquidity and Capital Resources

 

Cash flow from operations

Cash used in operating activities for the three months ended March 31, 2020 was $77,589 as compared to $42,026 cash used in operating activities for the three months ended March 31, 2019.

 

Cash Flows from Investing

Cash used in investing activities for the purchase of equipment and tooling for the three months ended March 31, 2020 was $7,500 as compared to $24,490 of cash used in investing activities for the three months ended March 31, 2019.

 

Cash Flows from Financing

For the three months ended March 31, 2020, we received $220,000 from the issuance of convertible debt and repaid $818 on our auto loan. For the three months ended March 31, 2019, we received $95,000 from convertible debt loans and repaid $772 on our auto loan

 

As of March 31, 2020, we owe $413,600 to our convertible debt holders.

 

Going Concern

 

As of March 31, 2020, there is substantial doubt regarding our ability to continue as a going concern as we have not generated sufficient cash flow to fund our proposed business.

 

13

 

 

We have suffered recurring losses from operations since our inception. In addition, we have yet to generate an internal cash flow from our business operations or successfully raised the financing required to develop our proposed business. As a result of these and other factors, our independent auditor has expressed substantial doubt about our ability to continue as a going concern. Our future success and viability, therefore, are dependent upon our ability to generate capital financing. The failure to generate sufficient revenues or raise additional capital may have a material and adverse effect upon us and our shareholders.

 

Management’s plans with regard to these matters encompass the following actions: (i) obtaining funding from new investors to alleviate our working capital deficiency, and (ii) implementing a plan to generate sales. Our continued existence is dependent upon our ability to resolve our liquidity problems and increase profitability in our current business operations. However, the outcome of management’s plans cannot be ascertained with any degree of certainty. Our financial statements do not include any adjustments that might result from the outcome of these risks and uncertainties.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Note 2 to the Financial Statements describes the significant accounting policies and methods used in the preparation of the Financial Statements. Estimates are used for, but not limited to, contingencies and taxes.  Actual results could differ materially from those estimates. The following critical accounting policies are impacted significantly by judgments, assumptions, and estimates used in the preparation of the Financial Statements.

 

We are subject to various loss contingencies arising in the ordinary course of business.  We consider the likelihood of loss or impairment of an asset or the incurrence of a liability, as well as our ability to reasonably estimate the amount of loss in determining loss contingencies.  An estimated loss contingency is accrued when management concludes that it is probable that an asset has been impaired, or a liability has been incurred and the amount of the loss can be reasonably estimated.  We regularly evaluate current information available to us to determine whether such accruals should be adjusted.

 

We recognize deferred tax assets (future tax benefits) and liabilities for the expected future tax consequences of temporary differences between the book carrying amounts and the tax basis of assets and liabilities.  The deferred tax assets and liabilities represent the expected future tax return consequences of those differences, which are expected to be either deductible or taxable when the assets and liabilities are recovered or settled.  Future tax benefits have been fully offset by a 100% valuation allowance as management is unable to determine that it is more likely than not that this deferred tax asset will be realized.

 

Recent Accounting Pronouncements

 

We have reviewed other recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of any other pronouncements to have an impact on our results of operations or financial position.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Each of our principal executive and principal financial officer has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a - 15(e) and 15d - 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on their evaluation, each such person concluded that our disclosure controls and procedures were not effective as of March 31, 2020 due to a lack of segregation of duties.

 

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.

 

Changes in Internal Control over Financial Reporting.

 

Our management has evaluated whether any change in our internal control over financial reporting occurred during the last fiscal quarter. Based on that evaluation, management concluded that there has been no change in our internal control over financial reporting during the relevant period that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

14

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the three months ended March 31, 2020, Armada Capital Partners LLC converted $20,850 and $110 of principal and interest, respectively, into 5,202,346 shares of common stock.

 

During the three months ended March 31, 2020, BHP Capital NY Inc converted $7,394 and $35 of principal and interest, respectively, into 1,919,620 shares of common stock.

 

During the three months ended March 31, 2020, Jefferson Street Capital LLC converted $13,750 of principal and $2,205 of interest, respectively, into 3,989,090 shares of common stock.

 

During the three months ended March 31, 2020, Odyssey Capital Funding LLC converted $35,000 of principal and $2,890 of interest, respectively, into 8,630,042 shares of common stock.

 

During the three months ended March 31, 2020, 36,769,439 shares of common stock were issued in conversion of 46,675,330 warrants.

 

For each of the above-referenced issuances, the Company relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended, provided by Section 4(a)(2) promulgated thereunder due to the fact that each was an isolated issuance to an accredited investor and did not involve a public offering of securities.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5. OTHER INFORMATION

 

None

 

15

 

 

ITEM 6. EXHIBITS

 

(a) Documents furnished as exhibits hereto:

 

Exhibit No.   Description
     
31.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Label Linkbase Document
101.PRE   XBRL Taxonomy Presentation Linkbase Document

 

16

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  REMSLEEP HOLDINGS, INC.
     
Date: May 18, 2020 By: /s/ Thomas J. Wood
    Thomas J. Wood
    Chief Executive Officer and Director
(Principal Executive Officer)
(Principal Financial and Accounting Officer)

 

 

17